Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress

Rhea-AI Summary

Nurix Therapeutics (Nasdaq: NRIX) announced that updated efficacy and safety data from its ongoing Phase 1a/b trial of BTK degrader bexobrutideg (NX-5948) in chronic lymphocytic leukemia (CLL) will be presented in an oral session at the 31st European Hematology Association Congress (EHA2026) in Stockholm, Sweden, on June 14, 2026.

Argus May 13 session

+1.38% close to close Open Argus

Details

News Market Reaction – NRIX

On May 13, the first trading day after this news, NRIX closed 1.38% above the previous close.

Data tracked by StockTitan Argus for the May 13 session.

Market Context

This announcement highlights that bexobrutideg’s updated Phase 1a/b efficacy and safety data in CLL ...

Analysis

This announcement highlights that bexobrutideg’s updated Phase 1a/b efficacy and safety data in CLL will be featured in an oral session at the 31st EHA Congress on June 14, 2026. It reinforces NRIX’s positioning in targeted protein degradation but does not disclose new response or safety figures in this release. In context of prior AACR updates and earnings reports, investors may watch the eventual EHA data details, subsequent trial progression, and any shifts in the broader CLL program strategy.

Key Figures

Conference dates: June 11–14, 2026 Session date: June 14, 2026 Session time: 11:00–12:15 CEST +3 more

Conference dates

June 11–14, 2026

EHA2026 congress in Stockholm

Session date

June 14, 2026

Bexobrutideg oral presentation session date

Session time

11:00–12:15 CEST

EHA2026 oral presentation session window

Congress edition

31st Congress

European Hematology Association EHA2026

Session room

A10-11 Hall

Location for CLL oral session

Abstract ID

S150

EHA2026 abstract identifier for bexobrutideg data

Historical Context

5 past events · Latest: Apr 22

5 events

1. Apr 22

   AACR data update

   24h Move

   -0.1%

   Preclinical and early clinical data across three oncology degrader programs at AACR 2026.

2. Apr 08

   Quarterly earnings

   24h Move

   -4.6%

   Q1 2026 financials with high R&D spend, net loss, and program milestones.

3. Apr 07

   Investor conference

   24h Move

   +3.5%

   CEO fireside chat announcement at the Needham Virtual Healthcare Conference.

4. Mar 23

   Conference presentations

   24h Move

   -1.7%

   Multiple oral and poster presentations planned at AACR 2026 on key degrader targets.

5. Jan 28

   Earnings and update

   24h Move

   -1.6%

   FY2025 results with strong bexobrutideg efficacy data and a $250M registered offering.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 1a/b, btk degrader, chronic lymphocytic leukemia, cll, +1 more

5 terms

phase 1a/b medical

"updated efficacy and safety data from the ongoing Phase 1a/b trial of BTK degrader"

Phase 1a/b is an early-stage clinical trial that tests a new drug or medical treatment in people to assess safety, find the right dose, and look for early signs it might work. For investors it matters because positive phase 1a/b results lower scientific and regulatory uncertainty and unlock value by advancing the program to larger trials, while negative results can sharply reduce a treatment’s commercial prospects—similar to passing or failing an initial safety inspection before mass production.

btk degrader medical

"Phase 1a/b trial of BTK degrader bexobrutideg (NX-5948) in patients with chronic"

A BTK degrader is a type of drug designed to attach to Bruton’s tyrosine kinase (BTK) — a protein that helps certain immune and cancer cells survive — and mark it for removal by the cell’s disposal system. For investors, BTK degraders matter because they can potentially work when older BTK-blocking drugs fail, may reduce long-term side effects, and could expand or shift market opportunities in cancer and autoimmune treatments.

chronic lymphocytic leukemia medical

"NX-5948) in patients with chronic lymphocytic leukemia (CLL) across lines of therapy"

A type of blood cancer in which a group of white blood cells grows slowly and abnormally, crowding out healthy cells and weakening the immune system; think of the body’s defense factory making too many defective parts that accumulate over time. Investors track it because clinical trial results, regulatory approvals, or new therapies for this disease can change treatment standards, patient demand, and revenue potential for companies developing drugs and diagnostics.

cll medical

"NX-5948) in patients with chronic lymphocytic leukemia (CLL) across lines of therapy"

Chronic lymphocytic leukemia (CLL) is a slow-growing blood cancer in which certain white blood cells accumulate and stop fighting infections properly, gradually crowding out healthy blood cells. For investors, CLL matters because successes or setbacks in drug trials, approvals, or new therapies can quickly change revenue prospects for biotech and pharmaceutical companies—similar to how a breakthrough or problem with a popular consumer product can swing a company’s sales outlook and stock price.

relapsed/refractory cll medical

"Session title: s449 Novel therapies in relapsed/refractory CLLSession date and time"

Chronic lymphocytic leukemia (CLL) that is described as relapsed/refractory means the cancer either came back after a period of improvement (relapsed) or never responded adequately to prior treatment (refractory). For investors, this signals a patient group with ongoing medical need and often drives demand for new or improved therapies, influences clinical trial design and approval chances, and can meaningfully affect a drug’s commercial potential — like a stubborn weed that needs a different herbicide.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that an abstract highlighting updated efficacy and safety data from the ongoing Phase 1a/b trial of BTK degrader bexobrutideg (NX-5948) in patients with chronic lymphocytic leukemia (CLL) across lines of therapy has been accepted for oral presentation at the 31st Congress of the European Hematology Association (EHA2026), taking place June 11-14, 2026, in Stockholm, Sweden.

Oral Presentation Details:

Title: Updated efficacy and safety data from an ongoing phase 1a/b trial of the BTK degrader bexobrutideg (NX-5948) in patients with CLL across lines of therapy
Presenter: Tahla Munir, MBChB, Ph.D.
Session title: s449 Novel therapies in relapsed/refractory CLL
Session date and time: June 14, 2026, 11:00 – 12:15 CEST
Session Room: A10-11 Hall
Abstract ID: S150

About Bexobrutideg (NX-5948)
Bexobrutideg is an investigational, orally bioavailable, brain penetrant, highly selective small molecule degrader of Bruton’s tyrosine kinase (BTK) currently being evaluated in the DAYBreak CLL-201 clinical trial (NCT07221500), a pivotal single-arm Phase 2 study of bexobrutideg in patients with relapsed or refractory CLL. Nurix also continues enrollment in the NX-5948-301 Phase 1a/1b clinical trial (NCT05131022) of bexobrutideg in patients with relapsed or refractory B cell malignancies. Additional information on the ongoing clinical trials can be accessed at clinicaltrials.gov.

About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of a preclinical stage degrader of STAT6, SAR448272/NX-3911, in collaboration with Sanofi, a clinical stage degrader of IRAK4, GS6791, in collaboration with Gilead, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by an AI-integrated discovery engine capable of tackling virtually any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in Brisbane, California. For additional information visit http://www.nurixtx.com.

Contacts:

Investors
Kris Fortner
Nurix Therapeutics, Inc.
kfortner@nurixtx.com

Sylvia Wheeler
Wheelhouse Life Science Advisors
swheeler@wheelhouselsa.com

Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

Kris Fortner
Nurix Therapeutics, Inc.
Kfortner@nurixtx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nurix Therapeutics (NRIX) announce about bexobrutideg at EHA2026?

Nurix Therapeutics announced an oral presentation of updated efficacy and safety data for BTK degrader bexobrutideg (NX-5948) in CLL at EHA2026. According to the company, the data come from an ongoing Phase 1a/b trial.

When and where will Nurix present bexobrutideg (NX-5948) CLL data at EHA2026?

The bexobrutideg CLL data will be presented on June 14, 2026, from 11:00–12:15 CEST at the EHA2026 Congress in Stockholm, Sweden. According to Nurix, the session will take place in Room A10-11 Hall.

What is the focus of Nurix’s Phase 1a/b trial of bexobrutideg (NX-5948) in CLL?

The Phase 1a/b trial evaluates updated efficacy and safety of BTK degrader bexobrutideg (NX-5948) in patients with chronic lymphocytic leukemia across lines of therapy. According to Nurix, these data form the basis of the upcoming EHA2026 oral presentation.

Who will present Nurix Therapeutics’ bexobrutideg (NX-5948) data at EHA2026?

The oral presentation will be given by Tahla Munir, MBChB, Ph.D. According to Nurix, the talk is part of the EHA2026 session titled “s449 Novel therapies in relapsed/refractory CLL,” featuring updated trial results in CLL.

What is the abstract ID and session information for Nurix (NRIX) bexobrutideg data at EHA2026?

The abstract ID is S150 for Nurix’s bexobrutideg CLL data at EHA2026. According to the company, it appears in session “s449 Novel therapies in relapsed/refractory CLL,” scheduled June 14, 2026, 11:00–12:15 CEST in Room A10-11 Hall.

What type of therapy is bexobrutideg (NX-5948) being developed by Nurix Therapeutics?

Bexobrutideg (NX-5948) is described as a BTK degrader being studied in chronic lymphocytic leukemia. According to Nurix, it is part of its pipeline of targeted protein degradation medicines in an ongoing Phase 1a/b clinical trial.